Table 3.

Response by investigator assessment (response-evaluable population)

	Dose escalation phase		Dose expansion phase: molecularly defined cohorts
	Q2D n = 22	QW n = 14	BRAF+ Naïve Q2D n  = 16 Cohort 1	BRAF+  Previously treated Q2D n = 6 Cohort 2	NRAS+  Naïve Q2D n  = 14 Cohort 3	NRAS +  Previously treated Q2D n  = 1 Cohort 4	BRAF/NRAS WT Naïve Q2D n  = 6 Cohort 5	BRAF/NRAS WT Previously Q2D n  = 9 Cohort 6	NRAS+  Naïve QW n  = 17 Cohort 9
Objective response rate	0	2 (14)	8 (50)	1 (17)	1 (7)	0	0	0	0
95% CI	–	2–43	25–75	< 1–64	< 1–34	–	–	–	–
Best overall response
Complete response	0	0	0	0	0	0	0	0	0
Partial response	0	2 (14)	8 (50)	1 (17)	1 (7)	0	0	0	0
Stable disease	5 (23)	4 (29)	2 (13)	3 (50)	4 (29)	0	1 (17)	3 (33)	9 (53)
Progressive disease	17 (77)	8 (57)	6 (38)	2 (33)	9 (64)	1 (100)	5 (83)	6 (67)	8 (47)

Data are n (%), unless otherwise stated

BRAF+ BRAF mutation-positive, DLT dose-limiting toxicity, NRAS+  NRAS mutation-positive, Q2D once every other day, QW once weekly, WT wild-type